RT @SCIDirector: SCI member Chris Garcia & colleagues found that #Tcell receptor-transgenic and CAR-modified CD8+ T cells that were expande…
RT @SCIDirector: SCI member Chris Garcia & colleagues found that #Tcell receptor-transgenic and CAR-modified CD8+ T cells that were expande…
RT @SCIDirector: SCI member Chris Garcia & colleagues found that #Tcell receptor-transgenic and CAR-modified CD8+ T cells that were expande…
We really enjoyed reviewing this paper from Warren J Leonard's group in our journal club yesterday. A well written, comprehensive and interesting approach to expanding stem-cell-like CD8+ T cells! https://t.co/XoaQxj7NpE
An engineered interleukin-2 promotes the expansion of CD8+ T cells without driving terminal differentiation, leading to improved anti-tumor responses in vivo. An engineered IL-2 partial agonist promotes CD8 + T cell stemness https://t.co/nG4zasicmI
How can #TCell stemness be preserved? A team at @NIH_NHLBI and their collaborators showed that an IL-2 partial agonist can promote CD8+ T cell expansion without driving differentiation. @Nature paper: https://t.co/zu6feZ2RBj Episode: https://t.co/322uBNhI
#がん研ジャーナルクラブ サイトカインもデザインする時代に!! IL-2刺激はT細胞の増殖と分化を促す。今回、T細胞の幹細胞性を保ったまま増殖を促す改変型IL-2(H9T)が報告された。H9Tで刺激されたT細胞は強い抗腫瘍活性を示すという。免疫療法に応用できそうな成果だ。 https://t.co/N4sNRU5omf
RT @PropThinker: Engineered IL-2 partial agonist shows CD8+ T cell expansion. Reduced binding to IL-2Rγ (CD132). Private Synthokine working…
An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/rjf0VLGb5g
RT @PropThinker: Engineered IL-2 partial agonist shows CD8+ T cell expansion. Reduced binding to IL-2Rγ (CD132). Private Synthokine working…
Engineered IL-2 partial agonist shows CD8+ T cell expansion. Reduced binding to IL-2Rγ (CD132). Private Synthokine working on partial agonist IL-2 IL-2 a fast moving space. $MDNA biomarker data for not alpha IL-2 asset by end 2021 and $NLTX Phase 1 2022
癌などの治療に抗原特異的T細胞を移植する療法においてIL-2などでのT細胞刺激では細胞が増えても幹細胞性を失って効果が下がってしまうようだが、IL-2を部分的に模倣した薬剤によって殺細胞効果のあるT細胞を増加させることが出来るようになったという論文。Nature誌。 https://t.co/t8VEPAUKZD
RT @PDRennert: there's regular IL-2, PEG-IL-2, Not-alpha IL-2, and ... partial agonist IL-2 CD8s love this last one https://t.co/wRwrvEmi…
RT @PDRennert: there's regular IL-2, PEG-IL-2, Not-alpha IL-2, and ... partial agonist IL-2 CD8s love this last one https://t.co/wRwrvEmi…
RT @PDRennert: there's regular IL-2, PEG-IL-2, Not-alpha IL-2, and ... partial agonist IL-2 CD8s love this last one https://t.co/wRwrvEmi…
RT @PDRennert: there's regular IL-2, PEG-IL-2, Not-alpha IL-2, and ... partial agonist IL-2 CD8s love this last one https://t.co/wRwrvEmi…
RT @PDRennert: there's regular IL-2, PEG-IL-2, Not-alpha IL-2, and ... partial agonist IL-2 CD8s love this last one https://t.co/wRwrvEmi…
there's regular IL-2, PEG-IL-2, Not-alpha IL-2, and ... partial agonist IL-2 CD8s love this last one https://t.co/wRwrvEmi7P
RT @albertomussetti: An engineered IL-2 partial agonist promotes CD8+ T cell stemness https://t.co/Yvefr19LiH
네이처 하이라이트:CD8+ T 세포 줄기세포성을 촉진하는 조작된 IL-2 Partial agonist https://t.co/14cC2TTLVP
An engineered IL-2 partial agonist promotes CD8+ T cell stemness https://t.co/Yvefr19LiH
An engineered IL-2 partial agonist promotes CD8(+) T cell stemness https://t.co/2gSB3v9l9o https://t.co/BS2SSVLlsw
New article: An engineered IL-2 partial agonist promotes CD8+ T cell stemness https://t.co/vEnF7fLfyo #kidneycancer #oncology https://t.co/B39mPteCkH
★H9Tは,消耗型とならずにT細胞リプログラムと拡充を引き起こす。 ★H9TはT細胞移植やCAR-T治療と組み合わせることで,生存期間が延長(マウス) https://t.co/xFYEwnYy74
An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/qgBdVbiKau
RT @Zihai: IL-2 never gets old! https://t.co/XZXcOr3QRj
RT @luglilab: An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/GLvVPt8isH
RT @gbantug2000: An engineered IL-2 partial agonist promotes CD8+ T cell stemness https://t.co/Dkv7znODXq
RT @luglilab: An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/GLvVPt8isH
RT @luglilab: An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/GLvVPt8isH
RT @Zihai: IL-2 never gets old! https://t.co/XZXcOr3QRj
IL-2 never gets old! https://t.co/XZXcOr3QRj
RT @luglilab: An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/GLvVPt8isH
An engineered IL-2 partial agonist promotes CD8+ T cell stemness https://t.co/Dkv7znODXq
RT @luglilab: An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/GLvVPt8isH
An engineered IL-2 partial agonist promotes CD8+ T cell stemness https://t.co/gHJwWh011h
RT @luglilab: An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/GLvVPt8isH
RT @luglilab: An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/GLvVPt8isH
RT @luglilab: An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/GLvVPt8isH
RT @luglilab: An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/GLvVPt8isH
RT @MauroCorradoBio: An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/72ESw1qKXo
RT @LemmonFerguson: This is a great story: https://t.co/Nse73BxfR0 https://t.co/DmM4LDZSZY
RT @MauroCorradoBio: An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/72ESw1qKXo
RT @MauroCorradoBio: An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/72ESw1qKXo
RT @luglilab: An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/GLvVPt8isH
An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/72ESw1qKXo
RT @luglilab: An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/GLvVPt8isH
An engineered IL-2 partial agonist promotes CD8+ T cell stemness | Nature https://t.co/GLvVPt8isH
An engineered IL-2 partial agonist promotes CD8+ T cell stemness #Leonard #Garcia @nrestifo labs https://t.co/G0uQxGvJ7B
This is a great story: https://t.co/Nse73BxfR0 https://t.co/DmM4LDZSZY
An engineered IL-2 partial agonist promotes CD8+ T cell stemness https://t.co/1GRwBaQSkw https://t.co/qeLr17EOL6 | #research #manuscripts @nature